Copeptin and risk stratification in patients with acute dyspnea

Table 3 Multivariate Cox regression analysis for 30-day mortality

	All patients		ADHF		No ADHF
Variable	HR for 30-day mortality	P -value	HR for 30-day mortality	P -value	HR for 30-day mortality	P -value
Copeptin ^a	4.58 (2.29 to 9.13)	< 0.0001	6.51 (2.83 to 14.95)	< 0.0001	1.87 (0.29 to 12.12)	0.51
BNP ^a	1.42 (0.71 to 2.86)	0.32	0.76 (0.23 to 2.50)	0.65	2.28 (0.49 to 10.67)	0.3
NT-proBNP ^a	3.17 (1.49 to 6.71)	0.003	3.84 (1.15 to 12.89)	0.029	5.32 (1.1 to 25.76)	0.038
Adjusted model including NT to proBNP or Copeptin
Copeptin ^a	3.88 (1.94 to 7.77)	< 0.001	5.99 (2.55 to 14.07)	< 0.0001	1.23 (0.17 to 9.14)	0.84
NT-proBNP ^a	2.74 (1.27 to 5.93)	0.01	2.78 (0.78 to 10.60)	0.11	5.26 (1.07 to 25.79)	0.041

Adjusted for age, gender, history of heart failure, glomerular filtration rate, diabetes, systolic blood pressure. ^a log-transformed to achieve normal distribution. BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; HR, hazard ratio.

ISSN: 1364-8535